Clinical Trial

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Study acronym: DANNOAC-AF
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in atrial fibrillation and atrial flutter across Danish hospitals and cardiology clinics.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-04-21; most recent amendment 2025-05-14.
Status change: Recruiting → Active, Not Recruiting 2025-05-14
Status change: Not Yet Recruiting → Recruiting 2017-04-30
Trial Details
NCT Number NCT03129490
Lead Sponsor Herlev and Gentofte Hospital
Conditions Atrial Fibrillation, Atrial Flutter
Enrollment 11,000 participants
Start Date 2023-04-01
Primary Completion 2027-10-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-18